Fecal Microbiota Transplant (FMT) Capsule for Improving the Efficacy of GI-aGVHD

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

UNKNOWN

Clinical Phase

EARLY_PHASE1

Total Enrollment

15 participants

Study Classification

INTERVENTIONAL

Study Start Date

2021-11-01

Study Completion Date

2023-03-02

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

This study aims to determine whether the fecal microbiota transplant (FMT) capsule improves the response rate of GI-aGVHD in patients with glucocorticoid-refractory acute graft vs. host disease after allogeneic stem cell transplantation

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

GVHD

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

NA

Intervention Model

SINGLE_GROUP

Primary Study Purpose

TREATMENT

Blinding Strategy

NONE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

FMT

60 capsules per day for 2 day

Group Type EXPERIMENTAL

FMT

Intervention Type BIOLOGICAL

Fecal Microbiota Transplantation

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

FMT

Fecal Microbiota Transplantation

Intervention Type BIOLOGICAL

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* 1\. GVHD within 100 days after allogeneic hematopoietic stem cell transplantation (allo HSCT);

2\. Age 18 - 65 years old, regardless of gender;

3\. Patients with grade 3 or 4 gastrointestinal involvement (aGVHD) according to the International Alliance (Magic) classification standard;

4\. Patients with glucocorticoid resistant GI aGVHD are diagnosed. According to the expert consensus of Chinese allogeneic hematopoietic stem cell transplantation for the treatment of hematological diseases (III) - acute graft-versus-host disease (2020 Edition), the definition of glucocorticoid resistant acute GVHD is Thomas' hematopoietic cell transplantation: stem cell transplantation (5th Edition) Glucocorticoid resistance was defined as PD at 3 days, NR at 7 days or Cr not reached at 14 days after first-line treatment.

5\. ECoG 3 points or less;

6\. Stop prophylactic antibiotics at least 12 hours before FMT treatment;

7\. Be able and willing to sign informed consent;

8\. Patients who are capable of swallowing capsules and can complete the study;

Exclusion Criteria

* 1\. There are active but uncontrolled infections, except GVHD complicated with infectious diarrhea;

2\. Gastrointestinal perforation, active gastrointestinal bleeding, small intestinal obstruction, toxic megacolon or other serious gastrointestinal diseases not caused by GVHD;

3\. Have a history of severe allergic reaction; Or known to be allergic to any ingredient of intestinal bacteria capsule xbi-302;

4\. Any serious disease that can increase the risk of patients participating in the study;

5\. Female subjects with positive pregnancy test and lactation, or female subjects of childbearing age who refuse to take contraceptive measures during the study;

6\. According to the judgment of the researcher, the patients with high dynamic diarrhea can not stay in the intestine for enough time to dissolve the capsule.

7\. HIV, HBV, HCV and syphilis are positive;

8\. After colectomy;

9\. Participate in other intervention clinical studies within 4 weeks before the screening period;

10\. The expected survival time is less than 12 weeks;

11\. The basic body function test is inferior to the following standards: total neutrophils (neu) \< 0.5 (x109 / L), platelet count (PLT) \< 30 (x109 / L), serum creatinine (CR) \> 1.5 times the maximum normal value (ULN), albumin (ALB) \< 25g / L;

12\. There is any situation that the researcher thinks is not suitable for inclusion (any history of medical history, treatment history or abnormal test data that may confuse the results of this study, interfere with the subject's whole participation in the study, or harm the interests of the subject).

Minimum Eligible Age

18 Years

Maximum Eligible Age

65 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Responsibility Role SPONSOR

Central Contacts

Reach out to these primary contacts for questions about participation or study logistics.

yanli zhao

Role: CONTACT

Phone: 0316-3306412

Email: [email protected]

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

XCT4843002

Identifier Type: -

Identifier Source: org_study_id